

Cover Story
A brief consult with an undergraduate earning a B or above in Statistics 101 might have acquainted Spectrum Pharmaceuticals executives with all the science that would have saved them from a devastating encounter with an FDA advisory committee.
Free
By Matthew Bin Han Ong
In Brief


Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- What NHS-Galleri taught us—and what it didn’t
- The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale















